Last reviewed · How we verify
Rapamycin-calcitriol combination
Rapamycin-calcitriol combination inhibits the mammalian target of rapamycin (mTOR) and vitamin D receptor (VDR) pathways.
Rapamycin-calcitriol combination inhibits the mammalian target of rapamycin (mTOR) and vitamin D receptor (VDR) pathways. Used for Multiple myeloma.
At a glance
| Generic name | Rapamycin-calcitriol combination |
|---|---|
| Also known as | Sirolimus-Rocaltrol combination |
| Sponsor | National Taiwan University Hospital |
| Drug class | mTOR inhibitor |
| Target | mTOR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The combination of rapamycin and calcitriol targets the mTOR pathway, which regulates cell growth and proliferation, and the VDR pathway, which is involved in calcium and phosphate homeostasis. This dual targeting may enhance the therapeutic efficacy of the combination in certain diseases.
Approved indications
- Multiple myeloma
Common side effects
- Thrombocytopenia
- Anemia
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: